BackGenetic Technologies Overview

Genetic Technologies Receivables

Track Genetic Technologies's receivables ($2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.13M
↑ 10.66% YoYΔ $204896.00 vs prior year quarter

Peer trimmed avg / median

Loading

Genetic Technologies Receivables History

Loading

Genetic Technologies vs. peers: Receivables Comparison

Loading

Genetic Technologies Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Genetic Technologies (GENE) FAQ

Genetic Technologies (GENE) currently reports a receivables of $2.1M as of June 2024. That compares with $1.9M in the prior-year period — up 10.7% year over year. Use the charts on this page to explore Genetic Technologies's receivables history and peer comparisons.

Genetic Technologies's receivables increased from $1.9M to $2.1M — a 10.7% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genetic Technologies reported $2.1M in receivables as of June 2024. That compares with $1.9M in the prior-year period — up 10.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $2.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Genetic Technologies, and consider following GENE for alerts when major investors trade the stock.

Genetic Technologies is classified in the Healthcare sector. On receivables, it currently shows $2.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GENE with unrelated industries.